A Study to Characterize the Time Course of Reversal of Opioid (Fentanyl)-Induced Respiratory Depression Following Administration of Nalmefene Autoinjector 1.5 mg (0.94% MgCl2) Intramuscular and Narcan® 4 mg Intranasal in Healthy Subjects
Phase: PHASE1
Conditions: Opioid Overdose
Sponsor: Purdue Pharma LP

Official Title: A Study to Characterize the Time Course of Reversal of Opioid 
(Fentanyl)-Induced Respiratory Depression Following Administration of 
Nalmefene Autoinjector 1.5 mg (0.94% MgCl2) Intramuscular·and Narcan® 4 mg 
Intranasal in Healthy Subjects 
 
NCT #: NCT06719986 
 
Date of Document: October 12, 2022